Drug Information

Drug General Information
Drug ID
D00GXL
Former ID
DIB016884
Drug Name
PBT-2
Synonyms
AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana
Drug Type
Small molecular drug
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 2 [523892]
Company
Prana biotechnology
Structure
Download
2D MOL

3D MOL
Formula
C12H12Cl2N2O
Canonical SMILES
CN(C)CC1=NC2=C(C=C1)C(=CC(=C2O)Cl)Cl
InChI
1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3
InChIKey
YZPOQCQXOSEMAZ-UHFFFAOYSA-N
PubChem Compound ID
10016012
PubChem Substance ID
14996799, 22446647, 44108107, 80332640, 135359929, 137970361, 233865477, 246074224
Target and Pathway
Target(s) Microtubule-associated protein tau Target Info Modulator [530731], [531616]
KEGG Pathway MAPK signaling pathway
Alzheimer's disease
NetPath Pathway IL2 Signaling Pathway
EGFR1 Signaling Pathway
Pathway Interaction Database LPA receptor mediated events
Reelin signaling pathway
Reactome Caspase-mediated cleavage of cytoskeletal proteins
WikiPathways Notch Signaling Pathway
IL-2 Signaling Pathway
MAPK Signaling Pathway
Copper homeostasis
Kit receptor signaling pathway
BDNF signaling pathway
Integrated Pancreatic Cancer Pathway
Alzheimers Disease
Regulation of Microtubule Cytoskeleton
Apoptotic execution phase
IL-5 Signaling Pathway
References
Ref 523892ClinicalTrials.gov (NCT01590888) Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease. U.S. National Institutes of Health.
Ref 530731PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
Ref 531616Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.